Biofourmis and Beacon Health System have partnered for an in-home monitoring program specifically meant for patients with complex chronic diseases, including chronic obstructive pulmonary disease (COPD), during their post-discharge period. Patient-reported data will be automatically collected, analyzed, and presented in a continuously updated dashboard visible to clinicians.
People with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) may experience fewer acute disease exacerbations if they regularly use noninvasive ventilation at night, a small study in Greece reported. “Good” nighttime use of continuous positive airway pressure (CPAP), a type of noninvasive ventilation, also aided lung…
Chronic obstructive pulmonary disease (COPD) was associated with an increased risk of overall mortality, as well as higher chances of cardiovascular, respiratory, and cancer-associated deaths, in a group of people living in Finland, a recent study has found. While asthma was also linked to a higher mortality risk over…
Many people with chronic obstructive pulmonary disease (COPD) or asthma use their inhaler therapies incorrectly, according to a recent study conducted at a center in Turkey. “The misuse of inhalers has been an obstacle to both patients and clinicians for many years and unfortunately still remains a significant issue,”…
Measuring inflammatory markers during routine blood tests in people with chronic obstructive pulmonary disease (COPD) could acute exacerbations at risk of experiencing worse outcomes, according to a small literature review study. Specifically, the researchers suggest measuring the neutrophil-to-lymphocyte ratio (NLR) — an indicator of systemic or body-wide inflammation. The…
Pulmonx and the American Lung Association have partnered to educate patients and healthcare providers about treatment options, including endobronchial valves that can help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Led by the American Lung Association, the Treating Severe COPD…
AstraZeneca has acquired the exclusive rights to develop and commercialize C4X Discovery’s oral NRF2 activator for treating chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases. The activator program aims to harness the antioxidant and anti-inflammatory properties of NRF2 in these conditions, although COPD will be…
Pulmonx has won the green light in Japan to market its Zephyr Endobronchial Valve, a bronchoscope-placed device designed to help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). With the OK from the Japanese Ministry of Health, Labour and Welfare…
The U.S. Food and Drug Administration (FDA) has authorized EpiEndo Pharmaceuticals to conduct a Phase 2a clinical trial of its antibiotic treatment EP395 in people with chronic obstructive pulmonary disease (COPD). It will be the first test of the experimental therapy in COPD patients. The clinical trial…
Therapeutic Solutions International (TSOI) has launched a pharmaceutical spin-off — Breathe Biologics — that will take the lead in developing and marketing therapies for chronic obstructive pulmonary disease (COPD), including JadiCell, its investigational stem cell therapy. TSOI has licensed to Breathe Biologics the investigational new drug (IND) application for…
Get regular updates to your inbox.